Search Page
Save citations to file
Email citations
Send citations to clipboard
Add to Collections
Add to My Bibliography
Create a file for external citation management software
Your saved search
Your RSS Feed
Filters
Results by year
Table representation of search results timeline featuring number of search results per year.
Year | Number of Results |
---|---|
2017 | 1 |
2019 | 1 |
2023 | 1 |
2024 | 0 |
Search Results
3 results
Results by year
Filters applied: . Clear all
Quoted phrase not found in phrase index: "Grade 5 Pulmonary Fibrosis, CTCAE"
Page 1
Weight loss in nintedanib-treated patients with idiopathic pulmonary fibrosis.
Pulm Pharmacol Ther. 2023 Jun;80:102213. doi: 10.1016/j.pupt.2023.102213. Epub 2023 Mar 29.
Pulm Pharmacol Ther. 2023.
PMID: 37001796
Nintedanib is approved for the treatment of idiopathic pulmonary fibrosis (IPF). Weight loss is recognized as an adverse event during nintedanib treatment, and is a common complication exploitable as a prognostic indicator of IPF. ...In the model adjusting fo …
Nintedanib is approved for the treatment of idiopathic pulmonary fibrosis (IPF). Weight loss is recognized as an adverse event …
Efficacy of corticosteroid and intravenous cyclophosphamide in acute exacerbation of idiopathic pulmonary fibrosis: A propensity score-matched analysis.
Hozumi H, Hasegawa H, Miyashita K, Yasui H, Suzuki Y, Kono M, Karayama M, Furuhashi K, Hashimoto D, Enomoto N, Fujisawa T, Inui N, Nakamura Y, Yokomura K, Nakamura H, Suda T.
Hozumi H, et al.
Respirology. 2019 Aug;24(8):792-798. doi: 10.1111/resp.13506. Epub 2019 Feb 25.
Respirology. 2019.
PMID: 30803100
Free article.
BACKGROUND AND OBJECTIVE: Acute exacerbation (AE) is a leading cause of death in patients with idiopathic pulmonary fibrosis (IPF). Although optimal treatment for AE-IPF remains unclear, high-dose corticosteroids (CS) with/without immunosuppressants, including intra …
BACKGROUND AND OBJECTIVE: Acute exacerbation (AE) is a leading cause of death in patients with idiopathic pulmonary fibrosis ( …
Item in Clipboard
Low body surface area predicts hepatotoxicity of nintedanib in patients with idiopathic pulmonary fibrosis.
Ikeda S, Sekine A, Baba T, Yamanaka Y, Sadoyama S, Yamakawa H, Oda T, Okuda R, Kitamura H, Okudela K, Iwasawa T, Ohashi K, Takemura T, Ogura T.
Ikeda S, et al.
Sci Rep. 2017 Sep 7;7(1):10811. doi: 10.1038/s41598-017-11321-x.
Sci Rep. 2017.
PMID: 28883482
Free PMC article.
After the commercialization of nintedanib in Japan, a high incidence of hepatotoxicity resulting in treatment interruption was noted in idiopathic pulmonary fibrosis (IPF) patients treated with nintedanib in our hospital. ...Body surface area (BSA) was significantly …
After the commercialization of nintedanib in Japan, a high incidence of hepatotoxicity resulting in treatment interruption was noted in idio …
Item in Clipboard
Cite
Cite